Overview

Peripheral white blood cells (PBMCs)
PBMCs driven into apoptosis through cellular stress have been shown to be highly potent in experimental wound healing, stroke, spinal cord injury, acute and chronic infarction models and prevention of ischemia reperfusion injury.

A systemic formulation derived from such PBMCs is developed as APO-1 (APOSECTM), whereas the topical formulation is named APO-2 (APOSECTM). Both formulations are prepared by a proprietary process from whole blood drawn from healthy donors.

For APO-1 (APOSECTM), the white blood cell fraction is obtained by leukapheresis or Ficoll gradient centrifugation. The leukocytes are resuspended in a GMP-approved culture medium and gamma-irradiated for a short period of time. This treatment leads to more than 70% of cells going into apoptosis.

Following incubation, the cell pellet is discarded and the culture supernatant is pooled, processed and lyophilized. For topical application, the product is formulated into suitable forms, e.g., creams, lotions or hydrogels. For systemic application, a simple buffered solution is prepared and injected either systemically or locally with suitable catheter devices.

Latest News
Mar
31

MarsyasI - clinical phase 1 study completed

[more]

Nov
24

Paper on content analysis of APOSEC recently published

[more]